Straits Times Index
3,343.90 +13.89 (+0.42%) Nikkei
38,776.56 +286.39 (+0.74%) Hang Seng
18,516.80 +91.84 (+0.50%) FTSE 100
8,246.95 +14.91 (+0.18%) Bitcoin USD
70,847.49 -179.44 (-0.25%) CMC Crypto 200
1,520.57 +46.83 (+3.18%)
NVO Jul 2024 105.000 put
- Reuters
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed. The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world's highest number of people who are overweight or obese. Ozempic won approval from China in 2021 and Novo Nordisk saw sales of the drug in the greater China region double to 4.8 billion Danish Krone ($698 million) last year.
- GuruFocus.com
William Blair Commentary: Waistlines and GLP1-s--Expanding in Unison
By Thomas A. Sternberg, CFA, Partner and Dasha Fomina
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiate
